%PDF-1.4
%
30 0 obj
<>
endobj
27 0 obj
<>
endobj
81 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T10:36:53Z
2024-03-28T18:46:28-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T18:46:28-07:00
application/pdf
Heather
2001-36.feb
uuid:2832b155-1dd2-11b2-0a00-b20827bd3700
uuid:2832b157-1dd2-11b2-0a00-5b0000000000
endstream
endobj
16 0 obj
<>
endobj
17 0 obj
<>
endobj
31 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
95 0 obj
[99 0 R]
endobj
96 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.2265 Tw 9.7 0 0 10 54 712.2551 Tm
(arthritis with sicca symptoms)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 174.5345 715.5551 Tm
(12)Tj
0 Tc 0.22639 Tw 9.7 0 0 10 180.8395 712.2551 Tm
[(. )17.8 (The results in the present)]TJ
0.2406 Tw -13.0762 -1.2 Td
(study also illustrate that there is no significant decline in)Tj
0.0956 Tw 0 -1.2 TD
(exocrine gland function over time, making it less likely that)Tj
0.02499 Tw T*
(lymphocytic infiltration causes the glandular dysfunction.)Tj
-0.002 Tw 1.2371 -1.2 Td
(This study indicates that immunological factors are associ-)Tj
-0.00011 Tc 0.1111 Tw -1.2371 -1.2 Td
[(ated with low salivary flow in primary Sj\366gren\222)54.8 (s syndrome.)]TJ
0 Tc 0.1356 Tw T*
(Several autoantibodies have been suggested to be of patho-)Tj
0.2547 Tw T*
(genic importance for the development of SS)Tj
0.0005 Tc 0 Tw 6.3 0 0 6.5 240.1313 631.5551 Tm
(1,2)Tj
0 Tc 0.23689 Tw 9.7 0 0 10 248.0125 628.2551 Tm
[(. The )-17.8 (most)]TJ
0.0309 Tw -20.0013 -1.2 Td
(exciting development in this field is the evidence of antimus-)Tj
0.2677 Tw T*
(carinic acetylcholine receptor antibody mediated secretory)Tj
0.0231 Tw T*
(dysfunction in nod mice)Tj
0 Tw 6.3 0 0 6.5 148.6883 595.5551 Tm
(4)Tj
0.0231 Tw 9.7 0 0 10 151.8408 592.2551 Tm
(. It has also recently been found that)Tj
-0.00011 Tc -0.00481 Tw -10.0867 -1.2 Td
(the acinar cells of patients with primary SS do possess a func-)Tj
0 Tc 0.0811 Tw T*
(tional receptor system)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 141.2216 571.5551 Tm
(17)Tj
0 Tc 0.0811 Tw 9.7 0 0 10 147.5266 568.2551 Tm
[(. )17.8 (This gives a new perspective to the)]TJ
0.1425 Tw -9.6419 -1.2 Td
(pathogenesis and hopefully also the treatment of a disorder)Tj
0.0493 Tw T*
(that is one of the most common inflammatory rheumatic dis-)Tj
-0.00011 Tc 0 Tw T*
(eases)Tj
0.0005 Tc 6.3 0 0 6.5 74.461 535.5551 Tm
(1,2)Tj
0 Tc 9.7 0 0 10 82.3422 532.2551 Tm
(.)Tj
/TT1 1 Tf
-0.00011 Tc -2.9219 -2.4 Td
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
0 Tc 0.0564 Tw 7.76 0 0 8 54 498.2551 Tm
[(I am grateful for the help of Dr)54.9 (. )17.8 (T)69.8 (ore R)39.8 (ygh, who contributed to the registra-)]TJ
-0.0049 Tw 0 -1.25 TD
(tion of these patients in 1992, and the help of the Department of Immuno\
logy)Tj
0.1181 Tw T*
[(and Microbiology)64.9 (, Haukeland University Hospital, in doing the serological)]TJ
0.23911 Tw T*
(analysis. Colleagues at the Broegelmann Research Laboratory have con-)Tj
-0.0226 Tw T*
[(tributed to fruithful discussion about immunological aspects of Sj\366gr\
en\222)54.9 (s syn-)]TJ
-0.0174 Tw T*
[(drome. I am also grateful for the help of the clinical and laboratory st\
af)17.8 (f at the)]TJ
0.28709 Tw T*
[(Department of Rheumatology)64.9 (, Haukeland University Hospital. Finally)65 (, I)]TJ
0.02499 Tw T*
[(highly appreciate the patients who participated in the study)64.9 (.)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 9.7 0 0 10 54 404.2551 Tm
(REFERENCES)Tj
/TT0 1 Tf
0.02499 Tw 7.76 0 0 8 61.18 394.2551 Tm
[(1.)-515.6 (Jonsson R, Haga H-J, Gordon )17.7 (T)73.9 (. Sj\366gren\222)54.8 (s syndrome. In: Koopman)]TJ
0 Tc 1.2655 -1.25 Td
[(WJ, editor)54.9 (. )54.8 (Arthritis and allied conditions. )54.8 (A)-219.8 (textbook of rheumatology)64.9 (.)]TJ
T*
[(14th ed. Philadelphia: Lippincott-W)39.8 (illiams & )17.8 (W)39.8 (ilkins; 2000:1828-49.)]TJ
-1.2655 -1.25 Td
[(2.)-515.5 (Jonsson R, Haga H-J, Gordon )17.7 (T)74 (. Current concepts on diagnosis,)]TJ
1.2655 -1.25 Td
[(autoantibodies and therapy in Sj\366gren\222)54.9 (s syndrome [editorial]. Scand J)]TJ
T*
(Rheumatol 2000;29:341-8.)Tj
-1.2655 -1.25 Td
[(3.)-515.5 (Fujita H, Fujihara )17.7 (T)74 (, )17.7 (T)69.8 (akeuchi )17.7 (T)74 (,)0.1 ( Saito I, )17.7 (T)69.8 (subota K. Lacrimation and)]TJ
1.2655 -1.25 Td
(salivation are not related to lymphocytic infiltration in lacrimal and)Tj
T*
[(salivary glands in MRL)-238.1 (lpr/lpr mice. )54.9 (Adv Exp Med Biol)]TJ
0 Tw T*
(1998;438:941-8.)Tj
0.02499 Tw 32.7552 51.2843 Td
[(4.)-515.5 (Nguyen KH, Brayer J, Cha S, et al. Evidence for antimuscarinic)]TJ
1.2655 -1.25 Td
(acetylcholine receptor antibody-mediated secretory dysfunction in nod)Tj
T*
[(mice. )54.9 (Arthritis Rheum 2000;43:2297-306.)]TJ
-0.00011 Tc -1.2655 -1.25 Td
[(5.)-515.6 (Pedersen )54.8 (AM, Reibel J, Nauntofte B. Primary Sj\366gren\222)54.8 (s syndrome:)]TJ
0 Tc 1.2655 -1.25 Td
(subjective symptoms and salivary findings. J Oral Pathol Med)Tj
0 Tw T*
[(1999;28:303-1)36.9 (1.)]TJ
0.0249 Tw -1.2655 -1.25 Td
[(6.)-515.5 (V)60.1 (itali C, Bombardieri S, Moutsopoulos HM, et al. )54.8 (Assessment of the)]TJ
-0.00011 Tc 1.2655 -1.25 Td
[(European Classification Criteria for Sj\366gren\222)54.8 (s syndrome in a series of)]TJ
0 Tc T*
[(clinically defined cases: results of a prospective multicenter study)64.9 (. )54.9 (Ann)]TJ
T*
[(Rheum Dis 1996;55:1)36.8 (16-21.)]TJ
-0.00011 Tc -1.2655 -1.25 Td
[(7.)-515.6 (Greenspan JS, Daniels )17.7 (TE, )17.7 (T)69.7 (alal N, Sylvester RA. )17.7 (The histopathology)]TJ
1.2655 -1.25 Td
[(of Sj\366gren\222)54.8 (s syndrome in labial salivary gland biopsies. Oral Sur)17.7 (g)]TJ
0 Tc 0 Tw T*
(1974;7:217-29.)Tj
0.0249 Tw -1.2655 -1.25 Td
[(8.)-515.5 (Haga H-J, Hulten B, Bolstad )54.8 (AI, Ulvestad E, Jonsson R. Reliability)]TJ
-0.00011 Tc 1.2655 -1.25 Td
[(and sensitivity of diagnostic tests for primary Sj\366gren\222)54.8 (s syndrome. )]TJ
0 Tc T*
(J Rheumatol 1999;26:604-8.)Tj
-1.2655 -1.25 Td
[(9.)-515.5 (Haga H-J, Jonsson R. )17.7 (The influence of age on disease manifestations)]TJ
-0.00011 Tc 1.2655 -1.25 Td
[(and serological characteristics in primary Sj\366gren\222)54.8 (s syndrome. Scand J)]TJ
0 Tc T*
(Rheumatol 1999;28:229-32.)Tj
-0.00011 Tc -1.7655 -1.25 Td
[(10.)-515.6 (Dawes C. Physiological factors af)17.7 (fecting salivary flow rate, oral sugar)]TJ
0 Tc 1.7655 -1.25 Td
(clearance and the sensation of dry mouth in men. J Dent Res)Tj
0 Tw T*
(1987;66:648-53.)Tj
0.0249 Tw -1.7286 -1.25 Td
[(1)36.9 (1.)-515.5 (T)34.9 (ishler M, )36.8 (Y)100.1 (aron I, Shirazi I, )36.8 (Y)100.1 (aron M. Saliva: )54.8 (An additional tool in)]TJ
1.7286 -1.25 Td
[(Sj\366gren\222)54.9 (s syndrome. Semin )54.8 (Arthritis Rheum 1997;27:173-9.)]TJ
-1.7655 -1.25 Td
[(12.)-515.5 (Uhlig )17.7 (T)74 (, Kvien )17.7 (TK, Liaaen Jensen J, )54.8 (Axell )17.7 (T)74 (. Sicca symptoms, saliva)]TJ
1.7655 -1.25 Td
(and tear production, and disease variables in 636 patients with)Tj
T*
[(rheumatoid arthritis. )54.9 (Ann Rheum Dis 1999;58:415-22.)]TJ
-0.00011 Tc -1.7655 -1.25 Td
[(13.)-515.6 (Jonsson R, Kroneld U, B\344ckman K, Magnusson B, )17.7 (T)69.7 (arkowski )54.8 (A.)]TJ
1.7655 -1.25 Td
[(Progression of sialoadenitis in Sj\366gren\222)54.8 (s syndrome. Br J Rheumatol)]TJ
0 Tc 0 Tw T*
(1993;32:578-81.)Tj
0.0249 Tw -1.7655 -1.25 Td
[(14.)-515.5 (Lundstrom IM, Lindstrom FD. Subjective and clinical oral symptoms)]TJ
1.7655 -1.25 Td
[(in patients with primary Sj\366gren\222)54.9 (s syndrome. Clin Exp Rheumatol)]TJ
0 Tw T*
(1995;13:725-31.)Tj
0.0249 Tw -1.7655 -1.25 Td
[(15.)-515.5 (Bivona PL. Xerostomia. )54.8 (A)-219.8 (common problem among the elderly)64.9 (. NY)]TJ
1.7655 -1.25 Td
(State Dent J 1998;64:46-52.)Tj
-1.7655 -1.25 Td
[(16.)-515.5 (Astor FC, Hanft KL, Ciocon JO. Xerostomia: a prevalent condition in)]TJ
1.7655 -1.25 Td
[(the elderly)64.9 (. Ear Nose )17.7 (Throat J 1999;78:476-9.)]TJ
-0.00011 Tc -1.7655 -1.25 Td
[(17.)-515.6 (Pedersen )54.8 (AM, Dissing S, Fahrenkrug J, Hannibal J, Reibel J,)]TJ
0 Tc 1.7655 -1.25 Td
(Nauntofte B. Innervation pattern and Ca)Tj
0 Tw 5.04 0 0 5.2 460.9429 337.1693 Tm
(2)Tj
0.02499 Tw 7.76 0 0 8 465.5989 334.5293 Tm
(signalling in labial salivary)Tj
-16.8298 -1.25 Td
[(glands of healthy individuals and patients with primary Sj\366gren\222)54.9 (s)]TJ
T*
(syndrome. J Oral Pathol Med 2000;29:97-109.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:2)Tj
0 Tw -46.2952 -0.0313 Td
(308)Tj
ET
0 0 0 0 scn
/GS0 gs
104.21 59.08 407.5 -10.83 re
f*
0.5 w
104.21 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
72 0 obj
<>
endobj
86 0 obj
<>
endobj
36 0 obj
<>
endobj
43 0 obj
<>
endobj
34 0 obj
<>
endobj
33 0 obj
<>
endobj
62 0 obj
<>stream
HV pTU=!Y瓈Iڰ@:aKYB#aR"B5K0L10&LQ@
8E22?w¦US/'w_j`섬^u @)SRjWRsڒciWͨ|Fp$ 9Յ.ibueW53e""ܭr.=R. 䫔*"s@E*˶`mӿjDym[VՏ;bm>Yf#Q+DGu`lf
i}YRhP؏XhDw#Uچ(eAHl2F1K\;PKG})?
WV?^B400v&ƣeu
=>NOUZHϣ*V[;`FfL$wG|eb^N sDqȚc},;sN/c*2jv{1{g%b;o.'A;d%b8bE2GpjC1NTŢV,o{G|&'Er\7!V"VbuMjZm߃[BSCաcӊҭjkjdWW2`WGaGoLG 1Yjg=72>}ʻtٝd
3 !ΝyE/fό&BT1M
1G!j
fY
‸&nl&dLv&_rx*e\&ߕ
#UYr!}tm"#MU@fTӌ#ܶl<:UyO??g/<=-G"FALk\Co|\5t9^ia;toBEn
5+^.5
zw&:
okG61<"5\
۔To,&\ELS/103Z#c8C `ސ/1QFi`TE2x#rcʻ-LX#ZD-VR9AgLgtm-I^[㟩0"8Ϛ'M_ڝiGͫ'BQMn;?mqg6%,bɚCCy+aq%-Sچ^(Z$Q"@SHPѨ-oBH]̼y3fw3l#'+Vuiɕ
1gA, %p,1fx:vxm%N*ۃ ̷4+f;Y> +WAK.e9﵂B1qv
16 7ٺǫgO7s0ϓJ1hߓڣ6ңz$|F2 r>u(1O@\-˝dzAs y3;ٙ$V% A#ȏ@"a3Xf9r@ɻ"w4`d$:2DCd0u$BI쌿d(Lm: @N XtY' Y:~ E'd5t
> N~ d F: d7A' H';,@12aviY_Fې7q=Wrm̵pvuҐB
uV-[[Vv+w+q7*ŵZVeUlUZJI+sWaRn5GX&>|VFJWX
+EaEǟi~v~_)W\zlVK2_8$O?A*̒yڐ/#S8/P#.%jx
ydb